UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...
Arthritis affects millions of people, yet there’s a dearth of recommendations on exactly what products can help people manage the pain and discomfort it causes. This is especially important since ...